MA42946A - Sels et formes solides d'un antibiotique de type monobactame - Google Patents

Sels et formes solides d'un antibiotique de type monobactame

Info

Publication number
MA42946A
MA42946A MA42946A MA42946A MA42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A
Authority
MA
Morocco
Prior art keywords
salts
solid forms
monobactam antibiotic
oxo
amino
Prior art date
Application number
MA42946A
Other languages
English (en)
Other versions
MA42946B1 (fr
Inventor
Eric Aubin
Anthony Casarez
Andreas Fisch
Zaixing Li
Mika Lindvall
Heinz Ernst Moser
Michael Mutz
Folkert Reck
Bernd Ulrich Riebesehl
Marc Schoenhentz
Vijay Sethuraman
Robert Lowell Simmons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA42946A publication Critical patent/MA42946A/fr
Publication of MA42946B1 publication Critical patent/MA42946B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La fourniture de nouvelles formes solides, des sels et des polymorphes d'acide 1-(((z)-(1-(2-aminothiazol-4-yl)2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidine-3-yl)méthyl)-1-sulfoazetidin-3-yl)amino)éthylidène)amino)oxy)-cyclopropanecarboxylique (désigné ici en tant que composé x), des compositions pharmaceutiques les contenant et des procédés pour leur fabrication et leur utilisation en thérapie.
MA42946A 2015-09-23 2016-09-20 Sels et formes solides d'un antibiotique de type monobactame MA42946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23
PCT/CN2016/099482 WO2017050218A1 (fr) 2015-09-23 2016-09-20 Sels et formes solides d'antibiotique monobactame

Publications (2)

Publication Number Publication Date
MA42946A true MA42946A (fr) 2018-08-01
MA42946B1 MA42946B1 (fr) 2020-10-28

Family

ID=58385723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42946A MA42946B1 (fr) 2015-09-23 2016-09-20 Sels et formes solides d'un antibiotique de type monobactame

Country Status (26)

Country Link
US (1) US10919887B2 (fr)
EP (1) EP3353175B1 (fr)
JP (1) JP6837480B2 (fr)
KR (1) KR102749337B1 (fr)
CN (1) CN108137573B (fr)
AU (1) AU2016327264B2 (fr)
CA (1) CA2999794C (fr)
CL (2) CL2018000745A1 (fr)
CY (1) CY1123509T1 (fr)
DK (1) DK3353175T3 (fr)
EA (2) EA202092620A1 (fr)
ES (1) ES2817537T3 (fr)
HR (1) HRP20201423T1 (fr)
HU (1) HUE050849T2 (fr)
IL (1) IL258254B (fr)
LT (1) LT3353175T (fr)
MA (1) MA42946B1 (fr)
MX (1) MX377532B (fr)
PH (1) PH12018500653B1 (fr)
PL (1) PL3353175T3 (fr)
PT (1) PT3353175T (fr)
RS (1) RS60805B1 (fr)
RU (1) RU2754180C2 (fr)
SI (1) SI3353175T1 (fr)
SM (1) SMT202000480T1 (fr)
WO (1) WO2017050218A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912656T3 (es) * 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
KR102146535B1 (ko) * 2017-08-16 2020-08-20 주식회사 엘지화학 Zif계 분말을 포함하는 백색 안료, 고분자 수지 필름 및 백색 안료를 사용하여 매질의 색을 변경하는 방법
WO2019092180A1 (fr) * 2017-11-10 2019-05-16 Novartis Ag Administration de monobactame pour le traitement d'une infection urinaire
EP3747883A4 (fr) 2018-01-29 2020-12-16 Medshine Discovery Inc. Composé b-lactame monocyclique pour traiter une infection bactérienne
WO2020125670A1 (fr) * 2018-12-18 2020-06-25 南京明德新药研发有限公司 APPLICATION D'UN COMPOSÉ β-LACTAME MONOCYCLIQUE EN PHARMACIE
KR102786898B1 (ko) * 2019-11-22 2025-03-25 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
US12491180B2 (en) 2019-12-19 2025-12-09 Shenzhen Optimum Biological Technology Co., Ltd Application of compound in treating pneumonia
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
US12516048B2 (en) 2020-08-06 2026-01-06 Ningxia Academy Of Agriculture And Forestry Sciences B-lactam compounds, their preparation and use as antibacterial agents
WO2022185240A1 (fr) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation d'un antibiotique monobactame
WO2022185241A1 (fr) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Procédé de fabrication d'un antibiotique monobactame
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205240A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Sulphonamide derivatives,being starting materials for producing beta-lactams
EP0048953B1 (fr) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Antibiotiques de bêta-lactame
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (fr) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd Derives 1-sulfo-2-oxoazetidine et leur procede de preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (fr) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
HU189290B (en) 1982-05-31 1986-06-30 Banyu Pharmaceutical Co Ltd,Jp Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd 2−オキソ−1−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
EA019520B1 (ru) 2008-10-31 2014-04-30 Сионоги Энд Ко., Лтд. Цефалоспорины, содержащие катехольную группу
CA2744756C (fr) * 2008-12-19 2013-05-28 Pfizer Inc. Monocarbames et leur utilisation comme agent antibacterien
JP5777725B2 (ja) 2010-11-29 2015-09-09 ファイザー・インク モノバクタム
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2015103583A1 (fr) 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactames et procédés de synthèse et d'utilisation de ces derniers
HUE042134T2 (hu) 2014-03-24 2019-06-28 Novartis Ag Monobaktám szerves vegyületek bakteriális fertõzések kezelésére

Also Published As

Publication number Publication date
CA2999794C (fr) 2023-08-15
US20180273522A1 (en) 2018-09-27
KR20180054816A (ko) 2018-05-24
WO2017050218A1 (fr) 2017-03-30
IL258254A (en) 2018-05-31
HUE050849T2 (hu) 2021-01-28
US10919887B2 (en) 2021-02-16
EP3353175B1 (fr) 2020-08-12
KR102749337B1 (ko) 2025-01-03
HK1257271A1 (en) 2019-10-18
BR112018005805A2 (pt) 2018-10-16
DK3353175T3 (da) 2020-09-14
CL2019003324A1 (es) 2020-04-17
LT3353175T (lt) 2020-10-12
JP6837480B2 (ja) 2021-03-03
EP3353175A4 (fr) 2019-06-26
EA202092620A1 (ru) 2021-06-30
PH12018500653B1 (en) 2022-05-04
IL258254B (en) 2021-02-28
SI3353175T1 (sl) 2020-11-30
RU2018114480A3 (fr) 2020-06-09
ES2817537T3 (es) 2021-04-07
CN108137573B (zh) 2021-06-11
CL2018000745A1 (es) 2018-06-22
JP2018528241A (ja) 2018-09-27
EP3353175A1 (fr) 2018-08-01
CA2999794A1 (fr) 2017-03-30
MA42946B1 (fr) 2020-10-28
CN108137573A (zh) 2018-06-08
AU2016327264B2 (en) 2019-06-27
PL3353175T3 (pl) 2021-02-22
PT3353175T (pt) 2020-09-10
HRP20201423T1 (hr) 2020-12-11
EA037569B1 (ru) 2021-04-15
PH12018500653A1 (en) 2018-10-01
RU2018114480A (ru) 2019-10-23
EA201890771A1 (ru) 2018-09-28
AU2016327264A1 (en) 2018-05-10
MX377532B (es) 2025-03-10
RS60805B1 (sr) 2020-10-30
CY1123509T1 (el) 2022-03-24
SMT202000480T1 (it) 2020-11-10
RU2754180C2 (ru) 2021-08-30
MX2018003592A (es) 2018-06-18

Similar Documents

Publication Publication Date Title
MA42946B1 (fr) Sels et formes solides d'un antibiotique de type monobactame
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
EP2727605A4 (fr) Analogue d'exendine-4 pégylé par du polyéthylène glycol ou un dérivé de celui-ci, son procédé de préparation et composition pharmaceutique pour prévenir ou traiter le diabète, le contenant en tant que principe actif
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
MX375068B (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
BR112022006608A2 (pt) Inibidores orais do fator d do complemento
BR112013020456A2 (pt) nova composição antifúngica
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
HRP20200161T1 (hr) (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja
MX2017010666A (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
EP2543374A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'ostéoarthrite contenant du rébamipide en tant que principe actif
EP3533450A4 (fr) Composition pharmaceutique destinée à prévenir ou à traiter une lésion d'ischémie-reperfusion, contenant de l'acide biliaire